BIOA B Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIOA B from our risk checks.
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr242.60 |
| 52 Week High | kr392.00 |
| 52 Week Low | kr175.00 |
| Beta | -0.14 |
| 1 Month Change | 25.31% |
| 3 Month Change | 15.09% |
| 1 Year Change | -24.52% |
| 3 Year Change | 104.21% |
| 5 Year Change | 225.20% |
| Change since IPO | 736.55% |
Recent News & Updates
Recent updates
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13
News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth
Dec 05BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate
Sep 15BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business
Aug 23Is BioArctic AB (publ) (STO:BIOA B) Trading At A 41% Discount?
Jun 03Shareholders Will Probably Not Have Any Issues With BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation
Apr 29Shareholder Returns
| BIOA B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 6.4% | 2.0% | -0.9% |
| 1Y | -24.5% | 10.1% | 14.2% |
Return vs Industry: BIOA B underperformed the Swedish Biotechs industry which returned 10.1% over the past year.
Return vs Market: BIOA B underperformed the Swedish Market which returned 14.2% over the past year.
Price Volatility
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BIOA B has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOA B's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 88 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
| BIOA B fundamental statistics | |
|---|---|
| Market cap | kr21.43b |
| Earnings (TTM) | -kr122.17m |
| Revenue (TTM) | kr252.21m |
85.0x
P/S Ratio-175.4x
P/E RatioIs BIOA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA B income statement (TTM) | |
|---|---|
| Revenue | kr252.21m |
| Cost of Revenue | kr77.90m |
| Gross Profit | kr174.31m |
| Other Expenses | kr296.48m |
| Earnings | -kr122.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 69.11% |
| Net Profit Margin | -48.44% |
| Debt/Equity Ratio | 0% |
How did BIOA B perform over the long term?
See historical performance and comparison